Phase 1 Relapse Multiple Myeloma Clinical Trials
3 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–3 of 3 trials
Recruiting
Phase 1
Cilta-Talq Fusion Study: A Phase 1b Study of Talquetamab Bridging Therapy Followed by Ciltacabtagene Autoleucel in Patients With Relapsed/Refractory Multiple Myeloma
Refractory Multiple MyelomaRelapse Multiple Myeloma
Medical College of Wisconsin31 enrolled1 locationNCT07093554
Recruiting
Phase 1
A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma
Multiple MyelomaRefractory Multiple MyelomaRelapse Multiple Myeloma
David Avigan25 enrolled2 locationsNCT06799026
Recruiting
Phase 1Phase 2
Study of CAR-BCMA, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against BCMA in Subjects With Multiple Myeloma
Multiple MyelomaRelapse Multiple Myeloma
Sheba Medical Center75 enrolled1 locationNCT05243212